NOTE 7 – INTANGIBLE ASSETS

Intangible assets at September 30, 2026 and December 31, 2025, consisted of the following:

During the three and nine months ended September 30, 2026 and 2025, the Company recognized amortization expense as follows: 

Licensed Technology

BP United – Drone Technology

On May 12, 2026, as amended, the Company entered into a license agreement with BP United for an exclusive, sublicensable, perpetual, fully paid-up, worldwide license (unrestricted field of use) to BP United’s patents, trademarks, trade secrets, and know-how, together with a worldwide non-compete covenant from BP United. The licensed technology is applicable to multiple fields of use and applications, including, without limitation, drones, cyber technology, and other applications as the Company may determine. Consideration for the transaction was $1,000,000 cash and 20,000,000 restricted shares, vesting in four equal installments (September 30, 2026, March 31, 2027, June 30, 2027, and September 30, 2027).

The Company recognized licensed technology assets of $5,470,400, representing the value of the 20,000,000 ordinary shares issuable, which was recorded as stock payable within additional paid-in capital. The $1,000,000 cash consideration, which relates to twelve months of support by the licensor, was recorded as prepaid technology, which is amortized to research and development expense over the twelve-month support period, with a corresponding intellectual property acquisition liability. The Company used the grant-date price, net of a discount for lack of marketability (“DLOM”) related to the issued shares being restricted (non-registered), of $0.27352 per share for the 20,000,000 shares issuable. In July 2026, the Company paid the $1,000,000 intellectual property acquisition liability in full. The Company determined that the useful life of the license is 15 years.

Pancreatic Cancer Biomarker and Algorithm License Agreement

In March 2025, the Company entered into a license agreement with Liquid Biosciences (“Liquid”) to access and use a portfolio of novel mRNA biomarkers and related algorithms for the detection of pancreatic cancer through blood-based testing. Total consideration for the license is $1.2 million, payable in scheduled installments during 2025 and 2026. The Company recorded the acquired intellectual property as an indefinite-lived intangible asset.

The Company capitalized the license costs and recorded the license as an intangible asset, with a corresponding liability for amounts unpaid. On July 21, 2026, the Company exercised its $1 purchase option and acquired the technology underlying the license.

As of September 30, 2026, the Company concluded that no events or changes in circumstances indicated that its indefinite-lived intangible asset was impaired or that the carrying amounts of its finite-lived intangible assets may not be recoverable.

During the nine months ended September 30, 2026, the Company paid $500,000, and the intellectual property acquisition liability related to the pancreatic cancer screening intellectual property recorded in March 2025 was paid in full.

Estimated future amortization expense for finite-lived intangible assets is as follows: